Andrew Tutt, MB ChB, PhD, director of the breast cancer research teams at The Institute of Cancer Research in London, talks with Julie Nangia, MD, about the results of the phase 3 OlympiA trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1 and BRCA2 pathogenic variants and high-risk HER2-negative primary breast cancer.
▷ Estimated Read Time:
1–2 minutes
SABCS Snippets: Results from the OlympiA trial
Connect with thousands of basic and translational scientists, multidisciplinary clinicians, regulatory and pharmaceutical partners, survivors, and patient advocates at the 49th annual San Antonio Breast Cancer Symposium. Complete your registration by Friday, September 25, to take advantage of discounted early registration rates.
Share: